Novartis Joins Harvard, Dana-Farber to Develop Cancer Therapy Systems

   By Marc Bisbal Arias

Novartis AG (NOVN.EB) said Tuesday that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop cancer therapy systems.

The Swiss pharmaceutical company has reached a collaboration and licensing agreement to develop biomaterial systems for its portfolio of immuno-oncology therapies.

The aim of the licensed systems is to overcome barriers that have hampered traditional cancer vaccines, it said.

Novartis will collaborate with the Wyss Institute to advance development of biomaterial systems that researchers have engineered to provide sustained delivery of immunotherapies and target specific types of cancer.

The technologies licensed under the agreement are owned or co-owned by Harvard University, Dana-Farber and the University of Michigan, it said.

Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com

(END) Dow Jones Newswires

March 20, 2018 03:02 ET (07:02 GMT)

Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024